ABIVAX Société Anonyme (ABVX) to Present Phase 3 UC Data at UEG Congress, Investor Call Scheduled

Core Insights - ABIVAX Société Anonyme is recognized as one of the 12 best performing healthcare stocks currently available for investment [1] - The company is focused on developing therapies for chronic inflammatory diseases, with its lead candidate, obefazimod, in advanced clinical trials [1] Group 1: Clinical Development - ABIVAX is a clinical-stage biotechnology company developing obefazimod, an oral miR-124 enhancer, which is currently in Phase 3 trials for ulcerative colitis (UC) and Phase 2b trials for Crohn's disease [1] - In July 2025, ABIVAX reported positive topline data from two Phase 3 induction trials in moderate to severe UC, showing a pooled clinical remission rate 16.4% higher than placebo, with the 50 mg dose achieving a 19.3% placebo-adjusted remission rate [3] - The company plans to submit U.S. and European regulatory applications in the second half of 2026 based on ongoing maintenance studies [3] Group 2: Upcoming Events - ABIVAX announced it will present late-breaking data from the ABTECT Phase 3 induction trials at the United European Gastroenterology (UEG) Congress in Berlin on October 6, 2025 [2] - The presentation will focus on eight-week efficacy results of obefazimod, including outcomes in patients who previously did not respond to advanced therapies [2] - An investor call and symposium on new treatment mechanisms for UC will be hosted alongside the congress [2] Group 3: Financial Position - To support its late-stage programs, ABIVAX strengthened its financial position with a $650 million (€554 million) public offering in July 2025 [4] - This funding extends the company's cash runway into the fourth quarter of 2027, enhancing investor confidence as it advances obefazimod toward potential approval and commercialization [4]